BOKU spin-off goes NASDAQ - and shines on Times Square!
F-star Therapeutics was founded in 2006 by the biotechnologists Florian Rüker, Gordana Wozniak-Knopp and colleagues. The company is based on the scientific invention to introduce antigen binding sites into non-conventional regions in antibody molecules. This method is used in the immunotherapy of various types of cancer. Currently, one such bispecific antibody is in clinical trials, two others are about to be tested. The company is growing steadily. Since November 23, F-star Therapeutics Inc. has been listed on the NASDAQ, as could be seen in New York's Times Square. BOKU is proud of this great success of its researchers!